|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
National Cancer Information Center (NCIC),
. Main Cancer Mortality Fraction in 2017. https://cancer.go.kr/lay1/S1T645C647/contents.do
|
|
3
|
Noone AM, Howlader N, Krapcho M, Miller D,
Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, et al:
SEER Cancer Statistics Review, 1975–2015National Cancer Institute;
Bethesda, MD: 2017
|
|
4
|
Fukui T and Mitsudomi T: Mutations in the
epidermal growth factor receptor gene and effects of EGFR-tyrosine
kinase inhibitors on lung cancers. Gen Thorac Cardiovasc Surg.
56:97–103. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tamura K, Okamoto I, Kashii T, Negoro S,
Hirashima T, Kudoh S, Ichinose Y, Ebi N, Shibata K, Nishimura T, et
al: Multicentre prospective phase II trial of gefitinib for
advanced non-small cell lung cancer with epidermal growth factor
receptor mutations: Results of the West Japan thoracic oncology
group trial (WJTOG0403). Br J Cancer. 98:907–914. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mitsudomi T and Yatabe Y: Mutations of the
epidermal growth factor receptor gene and related genes as
determinants of epidermal growth factor receptor tyrosine kinase
inhibitors sensitivity in lung cancer. Cancer Sci. 98:1817–1824.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee DH, Han JY, Yu SY, Kim HY, Nam BH,
Hong EK, Kim HT and Lee JS: The role of gefitinib treatment for
Korean never-smokers with advanced or metastatic adenocarcinoma of
the lung: A prospective study. J Thorac Oncol. 1:965–971. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Marchetti A, Martella C, Felicioni L,
Barassi F, Salvatore S, Chella A, Camplese PP, Iarussi T, Mucilli
F, Mezzetti A, et al: EGFR mutations in non-small-cell lung cancer:
Analysis of a large series of cases and development of a rapid and
sensitive method for diagnostic screening with potential
implications on pharmacologic treatment. J Clin Oncol. 23:857–865.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bos JL: Ras oncogenes in human cancer: A
review. Cancer Res. 49:4682–4689. 1989.PubMed/NCBI
|
|
10
|
Rodenhuis S, van de Wetering ML, Mooi WJ,
Evers SG, van Zandwijk N and Bos JL: Mutational activation of the
K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of
the lung. N Engl J Med. 317:929–935. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhao XD, Deng HB, Lu CL, Bao YX, Lu X and
Deng LL: Association of EGFR and KRAS mutations with expression of
p-AKT, DR5 and DcR1 in non-small cell lung cancer. Neoplasma.
64:182–191. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Campos-Parra AD, Zuloaga C, Manriquez ME,
Avilés A, Borbolla-Escoboza J, Cardona A, Meneses A and Arrieta O:
KRAS mutation as the biomarker of response to chemotherapy and
EGFR-TKIs in patients with advanced non-small cell lung cancer:
Clues for its potential use in second-line therapy decision making.
Am J Clin Oncol. 38:33–40. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Johnson ML, Sima CS, Chaft J, Paik PK, Pao
W, Kris MG, Ladanyi M and Riely GJ: Association of KRAS and EGFR
mutations with survival in patients with advanced lung
adenocarcinomas. Cancer. 119:356–362. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Soda M, Choi YL, Enomoto M, Takada S,
Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K,
Hatanaka H, et al: Identification of the transforming EML4-ALK
fusion gene in non-small-cell lung cancer. Nature. 448:561–566.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hong M, Kim RN, Song JY, Choi SJ, Oh E,
Lira ME, Mao M, Takeuchi K, Han J, Kim J and Choi YL: HIP1-ALK, a
novel fusion protein identified in lung adenocarcinoma. J Thorac
Oncol. 9:419–422. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hallberg B and Palmer RH: Mechanistic
insight into ALK receptor tyrosine kinase in human cancer biology.
Nat Rev Cancer. 13:685–700. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Togashi Y, Soda M, Sakata S, Sugawara E,
Hatano S, Asaka R, Nakajima T, Mano H and Takeuchi K: KLC1-ALK: A
novel fusion in lung cancer identified using a formalin-fixed
paraffin-embedded tissue only. PLoS One. 7:e313232012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zheng D, Wang R, Zhang Y, Pan Y, Cheng X,
Cheng C, Zheng S, Li H, Gong R, Li Y, et al: Prevalence and
clinicopathological characteristics of ALK fusion subtypes in lung
adenocarcinomas from Chinese populations. J Cancer Res Clin Oncol.
142:833–843. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Barlesi F, Mazieres J, Merlio JP,
Debieuvre D, Mosser J, Lena H, Ouafik L, Besse B, Rouquette I,
Westeel V, et al: Routine molecular profiling of patients with
advanced non-small-cell lung cancer: Results of a 1-year nationwide
programme of the French cooperative thoracic intergroup (IFCT).
Lancet. 387:1415–1426. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vidal J, Clave S, de Muga S, González I,
Pijuan L, Gimeno J, Remón J, Reguart N, Viñolas N, Gironés R, et
al: Assessment of ALK status by FISH on 1000 Spanish non-small cell
lung cancer patients. J Thorac Oncol. 9:1816–1820. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim TJ, Park CK, Yeo CD, Park K, Rhee CK,
Kim J, Kim SJ, Lee SH, Lee KY and Yoon HK: Simultaneous diagnostic
platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients
with non-small-cell lung cancer highlights significantly higher ALK
rearrangement rate in advanced stage. J Surg Oncol. 110:245–251.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ali G, Proietti A, Pelliccioni S, Niccoli
C, Lupi C, Sensi E, Giannini R, Borrelli N, Menghi M, Chella A, et
al: ALK rearrangement in a large series of consecutive non-small
cell lung cancers: Comparison between a new immunohistochemical
approach and fluorescence in situ hybridization for the screening
of patients eligible for crizotinib treatment. Arch Pathol Lab Med.
138:1449–1458. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang X, Zhang S, Yang X, Yang J, Zhou Q,
Yin L, An S, Lin J, Chen S, Xie Z, et al: Fusion of EML4 and ALK is
associated with development of lung adenocarcinomas lacking EGFR
and KRAS mutations and is correlated with ALK expression. Mol
Cancer. 9:1882010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu CW, Cai XY, Shao Y, Li Y, Shi MW, Zhang
LY, Wang L, Zhang YP, Wang LP and Tian YW: A case of lung
adenocarcinoma with a concurrent EGFR mutation and ALK
rearrangement: A case report and literature review. Mol Med Rep.
12:4370–4375. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wong DW, Leung EL, So KK, Tam IY, Sihoe
AD, Cheng LC, Ho KK, Au JS, Chung LP, Pik Wong M, et al: The
EML4-ALK fusion gene is involved in various histologic types of
lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer.
115:1723–1733. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim HJ, Choi EY, Jin HJ and Shin KC:
Relationship between EGFR mutations and clinicopathological
features of lung adenocarcinomas diagnosed via small biopsies.
Anticancer Res. 34:3189–3195. 2014.PubMed/NCBI
|
|
27
|
Lim JU, Yeo CD, Rhee CK, Kim YH, Park CK,
Kim JS, Kim JW, Lee SH, Kim SJ, Yoon HK, et al: Chronic obstructive
pulmonary disease-related non-small-cell lung cancer exhibits a low
prevalence of EGFR and ALK Driver Mutations. PLoS One.
10:e01423062015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bae NC, Chae MH, Lee MH, Kim KM, Lee EB,
Kim CH, Park TI, Han SB, Jheon S, Jung TH and Park JY: EGFR, ERBB2,
and KRAS mutations in Korean non-small cell lung cancer patients.
Cancer Genet Cytogenet. 173:107–113. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee T, Lee B, Choi YL, Han J, Ahn MJ and
Um SW: Non-small cell lung cancer with concomitant EGFR, KRAS, and
ALK mutation: Clinicopathologic features of 12 cases. J Pathol
Transl Med. 50:197–203. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ha SY, Choi SJ, Cho JH, Choi HJ, Lee J,
Jung K, Irwin D, Liu X, Lira ME, Mao M, et al: Lung cancer in
never-smoker Asian females is driven by oncogenic mutations, most
often involving EGFR. Oncotarget. 6:5465–5474. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee B, Lee T, Lee SH, Choi YL and Han J:
Clinicopathologic characteristics of EGFR, KRAS, and ALK
alterations in 6,595 lung cancers. Oncotarget. 7:23874–23884.
2016.PubMed/NCBI
|
|
32
|
Thunnissen E, Bubendorf L, Dietel M,
Elmberger G, Kerr K, Lopez-Rios F, Moch H, Olszewski W, Pauwels P,
Penault-Llorca F and Rossi G: EML4-ALK testing in non-small cell
carcinomas of the lung: A review with recommendations. Virchows
Arch. 461:245–257. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yatabe Y: ALK FISH and IHC: You cannot
have one without the other. J Thorac Oncol. 10:548–550. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Savic S, Diebold J, Zimmermann AK, Jochum
W, Baschiera B, Grieshaber S, Tornillo L, Bisig B, Kerr K and
Bubendorf L: Screening for ALK in non-small cell lung carcinomas:
5A4 and D5F3 antibodies perform equally well, but combined use with
FISH is recommended. Lung Cancer. 89:104–109. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cabillic F, Gros A, Dugay F, Begueret H,
Mesturoux L, Chiforeanu DC, Dufrenot L, Jauffret V, Dachary D,
Corre R, et al: Parallel FISH and immunohistochemical studies of
ALK status in 3244 non-small-cell lung cancers reveal major
discordances. J Thorac Oncol. 9:295–306. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
van der Wekken AJ, Pelgrim R, 't Hart N,
Werner N, Mastik MF, Hendriks L, van der Heijden EHFM,
Looijen-Salamon M, de Langen AJ, Staal-van den Brekel J, et al:
Dichotomous ALK-IHC is a better predictor for ALK inhibition
outcome than traditional ALK-FISH in advanced non-small cell lung
cancer. Clin Cancer Res. 23:4251–4258. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lindeman NI, Cagle PT, Aisner DL, Arcila
ME, Beasley MB, Bernicker EH, Colasacco C, Dacic S, Hirsch FR, Kerr
K, et al: Updated molecular testing guideline for the selection of
lung cancer patients for treatment with targeted tyrosine kinase
inhibitors: Guideline from the college of American pathologists,
the international association for the study of lung cancer, and the
association for molecular pathology. J Mol Diagn. 20:129–159. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jennings LJ, Arcila ME, Corless C,
Kamel-Reid S, Lubin IM, Pfeifer J, Temple-Smolkin RL, Voelkerding
KV and Nikiforova MN: Guidelines for validation of next-generation
sequencing-based oncology panels: A joint consensus recommendation
of the association for molecular pathology and college of American
pathologists. J Mol Diagn. 19:341–365. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
von Ahlfen S, Missel A, Bendrat K and
Schlumpberger M: Determinants of RNA quality from FFPE samples.
PLoS One. 2:e12612007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Glenn TC: Field guide to next-generation
DNA sequencers. Mol Ecol Resour. 11:759–769. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Camidge R, Kim HR, Ahn M, Yang JC, Han J,
Lee J, Hochmair M, Li JY, Chang G, Lee K, et al: PL02.03 brigatinib
vs crizotinib in patients with ALK inhibitor-naive advanced ALK+
NSCLC: First report of a phase 3 trial (ALTA-1L). J Thorac Oncol.
13:S184–S185. 2018. View Article : Google Scholar
|
|
42
|
Camidge DR, Kim HR, Ahn MJ, Yang JC, Han
JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, et al: Brigatinib
versus Crizotinib in ALK-positive non-small-cell lung cancer. N
Engl J Med. 379:2027–2039. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yang P, Kulig K, Boland JM,
Erickson-Johnson MR, Oliveira AM, Wampfler J, Jatoi A, Deschamps C,
Marks R, Fortner C, et al: Worse disease-free survival in
never-smokers with ALK+ lung adenocarcinoma. J Thorac Oncol.
7:90–97. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wu SG, Kuo YW, Chang YL, Shih JY, Chen YH,
Tsai MF, Yu CJ, Yang CH and Yang PC: EML4-ALK translocation
predicts better outcome in lung adenocarcinoma patients with
wild-type EGFR. J Thorac Oncol. 7:98–104. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Schilsky JB, Ni A, Ahn L, Datta S, Travis
WD, Kris MG, Chaft JE, Rekhtman N and Hellmann MD: Prognostic
impact of TTF-1 expression in patients with stage IV lung
adenocarcinomas. Lung Cancer. 108:205–211. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Won JK, Keam B, Koh J, Cho HJ, Jeon YK,
Kim TM, Lee SH, Lee DS, Kim DW and Chung DH: Concomitant ALK
translocation and EGFR mutation in lung cancer: A comparison of
direct sequencing and sensitive assays and the impact on
responsiveness to tyrosine kinase inhibitor. Ann Oncol. 26:348–354.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Gatalica Z, Xiu J, Swensen J and Vranic S:
Molecular characterization of cancers with NTRK gene fusions. Mod
Pathol. 32:147–153. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ardini E, Bosotti R, Borgia AL, De Ponti
C, Somaschini A, Cammarota R, Amboldi N, Raddrizzani L, Milani A,
Magnaghi P, et al: The TPM3-NTRK1 rearrangement is a recurring
event in colorectal carcinoma and is associated with tumor
sensitivity to TRKA kinase inhibition. Mol Oncol. 8:1495–1507.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Vaishnavi A, Capelletti M, Le AT, Kako S,
Butaney M, Ercan D, Mahale S, Davies KD, Aisner DL, Pilling AB, et
al: Oncogenic and drug-sensitive NTRK1 rearrangements in lung
cancer. Nat Med. 19:1469–1472. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Drilon A, Laetsch TW, Kummar S, DuBois SG,
Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo
AS, et al: Efficacy of larotrectinib in TRK fusion-positive cancers
in adults and children. N Engl J Med. 378:731–739. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Chen Y and Chi P: Basket trial of TRK
inhibitors demonstrates efficacy in TRK fusion-positive cancers. J
Hematol Oncol. 11:782018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Rolfo C and Raez L: New targets bring hope
in squamous cell lung cancer: Neurotrophic tyrosine kinase gene
fusions. Lab Invest. 97:1268–1270. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Amatu A, Sartore-Bianchi A and Siena S:
NTRK gene fusions as novel targets of cancer therapy across
multiple tumour types. ESMO Open. 1:e0000232016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Farago AF, Le LP, Zheng Z, Muzikansky A,
Drilon A, Patel M, Bauer TM, Liu SV, Ou SH, Jackman D, et al:
Durable clinical response to entrectinib in NTRK1-rearranged
non-small cell lung cancer. J Thorac Oncol. 10:1670–1674. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Liu Z, Wu L, Cao J, Yang Z, Zhou C, Cao L,
Wu H, Shen H, Jin M, Zhang Y, et al: Clinical characterization of
ERBB2 exon 20 insertions and heterogeneity of outcomes responding
to afatinib in Chinese lung cancer patients. Onco Targets Ther.
11:7323–7331. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Pillai RN, Behera M, Berry LD, Rossi MR,
Kris MG, Johnson BE, Bunn PA, Ramalingam SS and Khuri FR: HER2
mutations in lung adenocarcinomas: A report from the lung cancer
mutation consortium. Cancer. 123:4099–4105. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Sonobe M, Manabe T, Wada H and Tanaka F:
Lung adenocarcinoma harboring mutations in the ERBB2 kinase domain.
J Mol Diagn. 8:351–356. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Spector NL and Blackwell KL: Understanding
the mechanisms behind trastuzumab therapy for human epidermal
growth factor receptor 2-positive breast cancer. J Clin Oncol.
27:5838–5847. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Lee JW, Soung YH, Kim SY, Nam SW, Park WS,
Wang YP, Jo KH, Moon SW, Song SY, Lee JY, et al: ERBB2 kinase
domain mutation in the lung squamous cell carcinoma. Cancer Lett.
237:89–94. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Stephens P, Hunter C, Bignell G, Edkins S,
Davies H, Teague J, Stevens C, O'Meara S, Smith R, Parker A, et al:
Lung cancer: Intragenic ERBB2 kinase mutations in tumours. Nature.
431:525–526. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Liu S, Li S, Hai J, Wang X, Chen T, Quinn
MM, Gao P, Zhang Y, Ji H, Cross DAE and Wong KK: Targeting HER2
aberrations in non-small cell lung cancer with osimertinib. Clin
Cancer Res. 24:2594–2604. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
de Langen AJ, Jebbink M, Hashemi SMS,
Kuiper JL, de Bruin-Visser J, Monkhorst K, Thunnissen E and Smit
EF: Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC
that express HER2 after progression on EGFR TKI treatment. Br J
Cancer. 119:558–564. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Mazieres J, Barlesi F, Filleron T, Besse
B, Monnet I, Beau-Faller M, Peters S, Dansin E, Früh M, Pless M, et
al: Lung cancer patients with HER2 mutations treated with
chemotherapy and HER2-targeted drugs: Results from the European
EUHER2 cohort. Ann Oncol. 27:281–286. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
von Laffert M, Stenzinger A, Hummel M,
Weichert W, Lenze D, Warth A, Penzel R, Herbst H, Kellner U,
Jurmeister P, et al: ALK-FISH borderline cases in non-small cell
lung cancer: Implications for diagnostics and clinical decision
making. Lung Cancer. 90:465–471. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Ilie MI, Bence C, Hofman V, Long-Mira E,
Butori C, Bouhlel L, Lalvée S, Mouroux J, Poudenx M, Otto J, et al:
Discrepancies between FISH and immunohistochemistry for assessment
of the ALK status are associated with ALK ‘borderline’-positive
rearrangements or a high copy number: A potential major issue for
anti-ALK therapeutic strategies. Ann Oncol. 26:238–244. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Heyer EE, Deveson IW, Wooi D, Selinger CI,
Lyons RJ, Hayes VM, O'Toole SA, Ballinger ML, Gill D, Thomas DM, et
al: Diagnosis of fusion genes using targeted RNA sequencing. Nat
Commun. 10:13882019. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Ibrahim M, Parry S, Wilkinson D, Bilbe N,
Allen D, Forrest S, Maxwell P, O'Grady A, Starczynski J, Tanier P,
et al: ALK immunohistochemistry in NSCLC: Discordant staining can
impact patient treatment regimen. J Thorac Oncol. 11:2241–2247.
2016. View Article : Google Scholar : PubMed/NCBI
|
